Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Payables (2022 - 2025)

Oramed Pharmaceuticals' Payables history spans 4 years, with the latest figure at $17.4 million for Q4 2025.

  • For Q4 2025, Payables changed N/A year-over-year to $17.4 million; the TTM value through Dec 2025 reached $17.4 million, changed N/A, while the annual FY2025 figure was $17.4 million, N/A changed from the prior year.
  • Payables reached $17.4 million in Q4 2025 per ORMP's latest filing, up from $561000.0 in the prior quarter.
  • In the past five years, Payables ranged from a high of $77.9 million in Q3 2023 to a low of $561000.0 in Q3 2025.
  • Average Payables over 4 years is $11.2 million, with a median of $4.1 million recorded in 2023.
  • Peak YoY movement for Payables: skyrocketed 1722.78% in 2023, then tumbled 93.54% in 2024.
  • A 4-year view of Payables shows it stood at $4.2 million in 2022, then crashed by 53.5% to $1.9 million in 2023, then surged by 160.08% to $5.0 million in 2024, then surged by 246.88% to $17.4 million in 2025.
  • Per Business Quant, the three most recent readings for ORMP's Payables are $17.4 million (Q4 2025), $561000.0 (Q3 2025), and $2.2 million (Q2 2025).